Skip to Main Content

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite another round of gloomy clouds hovering over the Pharmalot campus. Our spirits remain sunny thanks to a bit of wisdom passed along by the Morning Mayor: Every brand new day should be unwrapped like a precious gift. So while you tug on the proverbial ribbon, we will brew another cup of stimulation and continue foraging for items of interest. Speaking of which, here are some tidbits. Enjoy your day and do keep us in mind when something interesting happens …

The U.K.’s National Institute for Health and Care Excellence is not recommending National Health Service use of the Spinraza treatment for spinal muscular atrophy sold by Biogen (BIIB), even after the company offered a discount, Pharmaphorum tells us. The cost-effectiveness agency is talking with the drug maker about a “managed access” scheme to limit the financial risks to the NHS. Such schemes are typically used for very rare drugs, but the SMA patient population is too large for Spinraza to be considered. There are between 1,200 and 2,500 children and adults in the U.K. with SMA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!